USE OF TUMOR-INDEPENDENT ANTIGENS IN IMMUNOTHERAPIES
The present disclosure provides methods of using a tumor-independent antigen in immunotherapies. The present disclosure provides methods of using a tumor-independent antigen in adoptive cell therapy.
1 . A method for treating a tumor in a subject in need thereof, comprising:
a tumor-marking step comprising administering a first composition to the subject at the tumor site, wherein the first composition comprises a tumor-independent antigen; and
introducing to the subject a tumor-independent antigen-specific immune cell.
2 . The method of claim 1 , wherein the subject has pre-existing immunity against the tumor-independent antigen.
3 . The method of claim 2 , wherein the pre-existing immunity comprises memory T cells and/or memory B cells having specificity for the tumor-independent antigen.
4 . The method of claim 1 , wherein the tumor-independent antigen is internalized by a cell of the tumor.
5 . (canceled)
6 . The method of claim 1 , wherein the tumor-independent antigen is provided via a carrier.
7 - 20 . (canceled)
21 . The method of claim 1 , wherein the tumor-independent antigen is a recall antigen.
22 - 27 . (canceled)
28 . The method of claim 1 , wherein the tumor marking-step comprises administering the first composition into the tumor or proximal to the tumor.
29 - 31 . (canceled)
32 . The method of claim 1 , wherein the tumor-independent antigen-specific immune cell is a tumor-independent antigen-specific T cell.
33 . The method of claim 1 , wherein the tumor-independent antigen-specific immune cell comprises an immune receptor.
34 . The method of claim 33 , wherein the immune receptor is a naturally occurring or synthetic immune receptor.
35 . The method of claim 33 , wherein the immune receptor is a chimeric antigen receptor (CAR) and/or a T cell receptor (TCR).
36 - 49 . (canceled)
50 . A method for treating a tumor in a subject in need thereof, comprising:
a tumor-marking step comprising administering a first composition to the subject at the tumor site, wherein the first composition comprises a tumor-independent antigen; and
administering to the subject a tumor-independent antigen-specific bispecific antibody.
51 . The method of claim 50 , wherein the subject has pre-existing immunity against the tumor-independent antigen.
52 . The method of claim 51 , wherein the pre-existing immunity comprises memory T cells and/or memory B cells having specificity for the tumor-independent antigen.
53 . The method of of claim 50 , wherein the tumor-independent antigen is internalized by a cell of the tumor.
54 . (canceled)
55 . The method of claim 50 , wherein the tumor-independent antigen is provided via a carrier.
56 - 69 . (canceled)
70 . The method of claim 50 , wherein the tumor-independent antigen is a recall antigen.
71 . The method of claim 50 , wherein the bispecific antibody comprises a first antigen-binding domain and a second antigen-binding domain.
72 . The method of claim 71 , wherein the first antigen-binding domain comprises specificity for the tumor-independent antigen.
73 . The method of claim 71 , wherein the second antigen-binding domain comprises specificity for an immune cell.
74 . (canceled)